# Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure

> **NCT03532009** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 182 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Sodium Zirconium Cyclosilicate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03532009
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-26
- **Primary completion:** 2020-05-22
- **Final completion:** 2020-05-22
- **Target enrollment:** 182 (ACTUAL)
- **Why stopped:** Study stopped early due to the COVID-19 pandemic
- **Last updated:** 2021-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03532009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03532009, "Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03532009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*